Literature DB >> 10374871

Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.

H Kawagoe1, R K Humphries, A Blair, H J Sutherland, D E Hogge.   

Abstract

To explore the possibility that deregulated HOX gene expression might commonly occur during leukemic hematopoiesis, we compared the relative levels of expression of these and related genes in phenotypically and functionally defined subpopulations of AML blasts and normal hematopoietic cells. Initially, a semi-quantitative RT-PCR technique was used to amplify total cDNA from total leukemic blast cell populations from 20 AML patients and light density cells from four normal bone marrows. Expression of HOX genes (A9, A10, B3 and B4), MEIS1 and MLL was easily detected in the majority of AML samples with the exception of two samples from patients with AML subtype M3 (which expressed only MLL). Low levels of HOXA9 and A10 but not B3 or B4 were seen in normal marrow while MLL was easily detected. PBX1a was difficult to detect in any AML sample but was seen in three of four normal marrows. Cells from nine AML patients and five normal bone marrows were FACS-sorted into CD34+CD38-, CD34+CD38+ and CD34-subpopulations, analyzed for their functional properties in long-term culture (LTC) and colony assays, and for gene expression using RT-PCR. 93 +/- 14% of AML LTC-initiating cells, 92 +/- 14% AML colony-forming cells, and >99% of normal LTC-IC and CFC were CD34+. The relative level of expression of the four HOX genes in amplified cDNA from CD34- as compared to CD34+CD38- normal cells was reduced >10-fold. However, in AML samples this down-regulation in HOX expression in CD34- as compared to CD34+CD38- cells was not seen (P < 0.05 for comparison between AML and normal). A similar difference between normal and AML subpopulations was seen when the relative levels of expression of MEIS1, and to a lesser extent MLL, were compared in CD34+ and CD34- cells (P < 0.05). In contrast, while some evidence of down-regulation of PBX1a was found in comparing CD34- to CD34+ normal cells it was difficult to detect expression of this gene in any subpopulation from most AML samples. Thus, the down-regulation of HOX, MEIS1 and to some extent MLL which occurs with normal hematopoietic differentiation is not seen in AML cells with similar functional and phenotypic properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10374871     DOI: 10.1038/sj.leu.2401410

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  83 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

2.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

3.  Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias.

Authors:  Zejuan Li; Roger T Luo; Shuangli Mi; Miao Sun; Ping Chen; Jingyue Bao; Mary Beth Neilly; Nimanthi Jayathilaka; Deborah S Johnson; Lili Wang; Catherine Lavau; Yanming Zhang; Charles Tseng; Xiuqing Zhang; Jian Wang; Jun Yu; Huanming Yang; San Ming Wang; Janet D Rowley; Jianjun Chen; Michael J Thirman
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

4.  Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Authors:  Sarah H Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D Aplan
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

5.  β-Catenin activates the HOXA10 and CDX4 genes in myeloid progenitor cells.

Authors:  Ling Bei; Chirag Shah; Hao Wang; Weiqi Huang; Rupali Roy; Elizabeth A Eklund
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

6.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Authors:  Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess
Journal:  Cancer Cell       Date:  2018-09-27       Impact factor: 31.743

7.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.

Authors:  Gang G Wang; Martina P Pasillas; Mark P Kamps
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

8.  Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif.

Authors:  E R Yassin; A M Abdul-Nabi; A Takeda; N R Yaseen
Journal:  Leukemia       Date:  2010-03-25       Impact factor: 11.528

9.  Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9.

Authors:  Enas R Yassin; Nayan J Sarma; Anmaar M Abdul-Nabi; James Dombrowski; Ye Han; Akiko Takeda; Nabeel R Yaseen
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

10.  Unique molecular characteristics of pediatric myxopapillary ependymoma.

Authors:  Valerie N Barton; Andrew M Donson; Bette K Kleinschmidt-DeMasters; Diane K Birks; Michael H Handler; Nicholas K Foreman
Journal:  Brain Pathol       Date:  2009-09-10       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.